Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18048802 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL18048801 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL18083928 | 0.79 | ROCK2 (0.72) | ROCK2 | |
| SCHEMBL18048663 | 0.79 | ROCK2 (0.56) | ROCK2 | |
| SCHEMBL18048664 | 0.77 | ROCK2 (0.60) | ROCK2 | |
| SCHEMBL18048721 | 0.77 | KMT2A (0.45) | ROCK2 | |
| SCHEMBL18048616 | 0.77 | ROCK2 (0.69) | ROCK2 | |
| SCHEMBL11029411 | 0.76 | HDAC6 (0.76) | ROCK2ROCK1 | |
| SCHEMBL18048689 | 0.76 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL18048733 | 0.75 | ROCK2 (0.71) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268360-B1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3268360-B1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10112929-B2 | Lactams as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| EP-3268360-A1 | LACTAMS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016144936-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144936-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | MYLK, ROCK1, RHOA | ROCK2 4/4885ROCK1 2/4885 |
| US-10112929-B2 | Lactams as inhibitors of rock | MYLK, ROCK1, RHOA | ROCK2 4/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.